Pharmaceutics (Oct 2022)

Autologous Marrow Mesenchymal Stem Cell Driving Bone Regeneration in a Rabbit Model of Femoral Head Osteonecrosis

  • Ilenia Mastrolia,
  • Andrea Giorgini,
  • Alba Murgia,
  • Pietro Loschi,
  • Tiziana Petrachi,
  • Valeria Rasini,
  • Massimo Pinelli,
  • Valentina Pinto,
  • Francesca Lolli,
  • Chiara Chiavelli,
  • Giulia Grisendi,
  • Maria Cristina Baschieri,
  • Giorgio De Santis,
  • Fabio Catani,
  • Massimo Dominici,
  • Elena Veronesi

DOI
https://doi.org/10.3390/pharmaceutics14102127
Journal volume & issue
Vol. 14, no. 10
p. 2127

Abstract

Read online

Osteonecrosis of the femoral head (ONFH) is a progressive degenerative disease that ultimately requires a total hip replacement. Mesenchymal stromal/stem cells (MSCs), particularly the ones isolated from bone marrow (BM), could be promising tools to restore bone tissue in ONFH. Here, we established a rabbit model to mimic the pathogenic features of human ONFH and to challenge an autologous MSC-based treatment. ON has been originally induced by the synergic combination of surgery and steroid administration. Autologous BM-MSCs were then implanted in the FH, aiming to restore the damaged tissue. Histological analyses confirmed bone formation in the BM-MSC treated rabbit femurs but not in the controls. In addition, the model also allowed investigations on BM-MSCs isolated before (ON-BM-MSCs) and after (ON+BM-MSCs) ON induction to dissect the impact of ON damage on MSC behavior in an affected microenvironment, accounting for those clinical approaches foreseeing MSCs generally isolated from affected patients. BM-MSCs, isolated before and after ON induction, revealed similar growth rates, immunophenotypic profiles, and differentiation abilities regardless of the ON. Our data support the use of ON+BM-MSCs as a promising autologous therapeutic tool to treat ON, paving the way for a more consolidated use into the clinical settings.

Keywords